| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Growth Hormone-Releasing Hormone | 11 | 2018 | 17 | 2.480 |
Why?
|
| Endoplasmic Reticulum Stress | 8 | 2021 | 99 | 1.280 |
Why?
|
| Peromyscus | 10 | 2021 | 14 | 1.260 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2018 | 114 | 0.980 |
Why?
|
| Mouth Neoplasms | 4 | 2016 | 206 | 0.850 |
Why?
|
| Unfolded Protein Response | 7 | 2021 | 70 | 0.830 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2018 | 32 | 0.820 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 5 | 2017 | 97 | 0.800 |
Why?
|
| Mouth Mucosa | 2 | 2011 | 51 | 0.740 |
Why?
|
| Ovarian Neoplasms | 4 | 2006 | 267 | 0.740 |
Why?
|
| Mouth Diseases | 2 | 2011 | 39 | 0.730 |
Why?
|
| Mice | 37 | 2022 | 8474 | 0.710 |
Why?
|
| Receptors, Pituitary Hormone-Regulating Hormone | 4 | 2008 | 4 | 0.680 |
Why?
|
| Animals, Outbred Strains | 2 | 2019 | 4 | 0.680 |
Why?
|
| Receptors, Neuropeptide | 4 | 2008 | 22 | 0.670 |
Why?
|
| Gastrointestinal Microbiome | 6 | 2022 | 122 | 0.650 |
Why?
|
| Animals | 50 | 2022 | 20881 | 0.640 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2016 | 629 | 0.640 |
Why?
|
| Fibroblasts | 11 | 2021 | 902 | 0.620 |
Why?
|
| Transcription Factor CHOP | 5 | 2020 | 28 | 0.610 |
Why?
|
| Breast Neoplasms | 8 | 2018 | 1536 | 0.570 |
Why?
|
| Stromal Cells | 6 | 2011 | 113 | 0.560 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 142 | 0.560 |
Why?
|
| Pemphigus | 1 | 2016 | 12 | 0.540 |
Why?
|
| Carcinogenesis | 5 | 2022 | 124 | 0.540 |
Why?
|
| Immunohistochemistry | 12 | 2012 | 1174 | 0.510 |
Why?
|
| Transcriptome | 6 | 2021 | 164 | 0.490 |
Why?
|
| Aging | 6 | 2021 | 911 | 0.480 |
Why?
|
| Biomedical Research | 1 | 2018 | 310 | 0.480 |
Why?
|
| Disease Models, Animal | 14 | 2022 | 2550 | 0.480 |
Why?
|
| Tongue Neoplasms | 2 | 2013 | 29 | 0.470 |
Why?
|
| Mice, Inbred C57BL | 18 | 2022 | 2791 | 0.440 |
Why?
|
| Diet, High-Fat | 8 | 2021 | 81 | 0.430 |
Why?
|
| Celiac Disease | 3 | 2022 | 17 | 0.430 |
Why?
|
| Colonic Neoplasms | 4 | 2022 | 299 | 0.420 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 561 | 0.410 |
Why?
|
| Eosinophilic Granuloma | 1 | 2011 | 1 | 0.390 |
Why?
|
| Oral Ulcer | 1 | 2011 | 22 | 0.390 |
Why?
|
| Colitis | 3 | 2022 | 156 | 0.390 |
Why?
|
| Neoplasms | 3 | 2018 | 1667 | 0.380 |
Why?
|
| Emodin | 2 | 2022 | 21 | 0.380 |
Why?
|
| Cell Line, Tumor | 9 | 2022 | 1851 | 0.380 |
Why?
|
| Humans | 46 | 2022 | 68618 | 0.380 |
Why?
|
| Gene Expression | 4 | 2020 | 770 | 0.380 |
Why?
|
| MicroRNAs | 3 | 2022 | 447 | 0.370 |
Why?
|
| Inflammation | 6 | 2021 | 1030 | 0.370 |
Why?
|
| Dextran Sulfate | 6 | 2022 | 88 | 0.360 |
Why?
|
| Azoxymethane | 6 | 2022 | 28 | 0.360 |
Why?
|
| Fasciitis | 1 | 2010 | 30 | 0.360 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1070 | 0.350 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2022 | 41 | 0.340 |
Why?
|
| Female | 34 | 2022 | 38074 | 0.340 |
Why?
|
| Actins | 2 | 2010 | 249 | 0.340 |
Why?
|
| Colon | 6 | 2021 | 168 | 0.330 |
Why?
|
| Macrophages | 5 | 2022 | 647 | 0.330 |
Why?
|
| Alternative Splicing | 5 | 2012 | 93 | 0.310 |
Why?
|
| Cell Movement | 4 | 2021 | 630 | 0.290 |
Why?
|
| Intestine, Small | 3 | 2022 | 89 | 0.290 |
Why?
|
| Epidermal Cyst | 1 | 2006 | 3 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2015 | 231 | 0.270 |
Why?
|
| Teratoma | 1 | 2006 | 22 | 0.270 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 1173 | 0.270 |
Why?
|
| Weight Loss | 2 | 2020 | 319 | 0.270 |
Why?
|
| Hepatocytes | 2 | 2020 | 205 | 0.250 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2017 | 235 | 0.240 |
Why?
|
| Endoplasmic Reticulum | 3 | 2012 | 148 | 0.240 |
Why?
|
| Adenocarcinoma | 4 | 2008 | 475 | 0.230 |
Why?
|
| Melanoma | 1 | 2008 | 335 | 0.230 |
Why?
|
| Carcinoma | 2 | 2005 | 215 | 0.230 |
Why?
|
| Weight Gain | 2 | 2021 | 135 | 0.230 |
Why?
|
| Homeostasis | 2 | 2022 | 291 | 0.220 |
Why?
|
| Intestinal Mucosa | 3 | 2022 | 219 | 0.220 |
Why?
|
| Endometrial Neoplasms | 2 | 2003 | 69 | 0.210 |
Why?
|
| Quercetin | 1 | 2022 | 16 | 0.210 |
Why?
|
| Fatty Liver | 2 | 2020 | 97 | 0.210 |
Why?
|
| Neoplasm Transplantation | 5 | 2021 | 160 | 0.210 |
Why?
|
| Helianthus | 1 | 2022 | 4 | 0.210 |
Why?
|
| Peptidomimetics | 1 | 2022 | 7 | 0.210 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 19 | 0.200 |
Why?
|
| Arthritis, Experimental | 1 | 2022 | 38 | 0.200 |
Why?
|
| Cells, Cultured | 7 | 2019 | 2673 | 0.200 |
Why?
|
| Male | 20 | 2022 | 37321 | 0.200 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2001 | 19 | 0.200 |
Why?
|
| Mice, Nude | 5 | 2021 | 294 | 0.200 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 42 | 0.200 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2022 | 160 | 0.200 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 1293 | 0.200 |
Why?
|
| Pair Bond | 1 | 2021 | 1 | 0.190 |
Why?
|
| Sermorelin | 1 | 2001 | 1 | 0.190 |
Why?
|
| Middle Aged | 14 | 2020 | 21147 | 0.190 |
Why?
|
| Somatostatin | 1 | 2001 | 36 | 0.190 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 59 | 0.190 |
Why?
|
| Heat-Shock Proteins | 3 | 2020 | 69 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1174 | 0.190 |
Why?
|
| Bombesin | 1 | 2000 | 4 | 0.190 |
Why?
|
| Genes, jun | 1 | 2000 | 13 | 0.190 |
Why?
|
| Genes, fos | 1 | 2000 | 22 | 0.190 |
Why?
|
| Paracrine Communication | 1 | 2020 | 31 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 157 | 0.180 |
Why?
|
| RNA, Messenger | 6 | 2016 | 1664 | 0.180 |
Why?
|
| Zoonoses | 1 | 2020 | 12 | 0.180 |
Why?
|
| Antioxidants | 1 | 2022 | 304 | 0.180 |
Why?
|
| Obesity | 2 | 2018 | 1076 | 0.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 87 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 163 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 710 | 0.180 |
Why?
|
| Liver Neoplasms | 3 | 2016 | 334 | 0.180 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2019 | 7 | 0.170 |
Why?
|
| Tumor Burden | 4 | 2022 | 132 | 0.170 |
Why?
|
| Diagnosis, Differential | 6 | 2015 | 1140 | 0.170 |
Why?
|
| Frailty | 1 | 2020 | 34 | 0.170 |
Why?
|
| Insulin-Secreting Cells | 2 | 2016 | 41 | 0.170 |
Why?
|
| Adipose Tissue | 1 | 2020 | 221 | 0.170 |
Why?
|
| Intestines | 1 | 2019 | 114 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2011 | 4848 | 0.160 |
Why?
|
| Wound Healing | 2 | 2011 | 260 | 0.160 |
Why?
|
| Antibodies | 1 | 2019 | 241 | 0.160 |
Why?
|
| Fluorouracil | 1 | 2019 | 130 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 37 | 0.160 |
Why?
|
| Islets of Langerhans | 2 | 2017 | 87 | 0.160 |
Why?
|
| Goblet Cells | 1 | 2018 | 9 | 0.160 |
Why?
|
| Skin | 1 | 2021 | 451 | 0.160 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2018 | 26 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2000 | 483 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 331 | 0.150 |
Why?
|
| Clodronic Acid | 1 | 2017 | 9 | 0.150 |
Why?
|
| Anticarcinogenic Agents | 1 | 2017 | 52 | 0.150 |
Why?
|
| Transplantation, Heterologous | 3 | 2008 | 122 | 0.150 |
Why?
|
| Aged | 8 | 2016 | 14862 | 0.150 |
Why?
|
| Cell Division | 4 | 2003 | 541 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2017 | 63 | 0.140 |
Why?
|
| Chemokine CCL3 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2016 | 4 | 0.140 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2016 | 2 | 0.140 |
Why?
|
| Aging, Premature | 1 | 2016 | 2 | 0.140 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 17 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 1085 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 852 | 0.140 |
Why?
|
| Desmogleins | 1 | 2016 | 4 | 0.140 |
Why?
|
| Iron Chelating Agents | 1 | 2016 | 31 | 0.140 |
Why?
|
| Pyridones | 1 | 2016 | 40 | 0.140 |
Why?
|
| Chemokine CCL8 | 1 | 2016 | 2 | 0.140 |
Why?
|
| Cytokines | 4 | 2022 | 866 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 160 | 0.130 |
Why?
|
| Monocytes | 1 | 2017 | 210 | 0.130 |
Why?
|
| Salivary Glands, Minor | 1 | 2015 | 7 | 0.130 |
Why?
|
| Liver | 5 | 2021 | 1118 | 0.130 |
Why?
|
| Papilloma, Inverted | 1 | 2015 | 8 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 3259 | 0.130 |
Why?
|
| Estradiol | 1 | 2016 | 176 | 0.130 |
Why?
|
| Estrogens | 1 | 2016 | 173 | 0.130 |
Why?
|
| Adult | 9 | 2016 | 21403 | 0.130 |
Why?
|
| Cell Line | 2 | 2016 | 1752 | 0.130 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 546 | 0.120 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 213 | 0.120 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2015 | 40 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 1026 | 0.120 |
Why?
|
| Body Weight | 3 | 2022 | 554 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 498 | 0.110 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2013 | 14 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 362 | 0.110 |
Why?
|
| Phenotype | 1 | 2016 | 947 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 13 | 0.110 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2013 | 15 | 0.110 |
Why?
|
| Gingival Neoplasms | 1 | 2013 | 13 | 0.110 |
Why?
|
| Angiolipoma | 1 | 2013 | 1 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2013 | 16 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 16 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 57 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 195 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 756 | 0.100 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 40 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 219 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 183 | 0.100 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2011 | 1 | 0.100 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2011 | 3 | 0.100 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2011 | 5 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2011 | 8 | 0.100 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2011 | 6 | 0.100 |
Why?
|
| Mouth Floor | 1 | 2011 | 9 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2011 | 19 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2011 | 29 | 0.100 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2011 | 40 | 0.100 |
Why?
|
| Mandible | 1 | 2011 | 53 | 0.100 |
Why?
|
| Vascular Malformations | 1 | 2011 | 19 | 0.100 |
Why?
|
| Eosinophils | 1 | 2011 | 60 | 0.100 |
Why?
|
| Glutens | 2 | 2022 | 10 | 0.100 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2001 | 52 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2016 | 305 | 0.090 |
Why?
|
| Antigens, CD19 | 2 | 2022 | 17 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2001 | 110 | 0.090 |
Why?
|
| Altitude | 2 | 2021 | 17 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 694 | 0.090 |
Why?
|
| Neck Dissection | 1 | 2010 | 55 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 492 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 91 | 0.090 |
Why?
|
| Sarcoma | 1 | 2010 | 70 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2010 | 147 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 74 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2016 | 1692 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2010 | 7277 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 508 | 0.080 |
Why?
|
| DNA | 1 | 2011 | 597 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 1033 | 0.080 |
Why?
|
| Ligamentum Flavum | 1 | 2008 | 3 | 0.080 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2008 | 6 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2022 | 2689 | 0.080 |
Why?
|
| Tunicamycin | 2 | 2019 | 10 | 0.070 |
Why?
|
| Ossification, Heterotopic | 1 | 2008 | 45 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2008 | 246 | 0.070 |
Why?
|
| Base Pair Mismatch | 1 | 2006 | 12 | 0.070 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2006 | 26 | 0.070 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 244 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2006 | 40 | 0.070 |
Why?
|
| Time Factors | 4 | 2017 | 4655 | 0.070 |
Why?
|
| Hepatomegaly | 1 | 2005 | 4 | 0.060 |
Why?
|
| DNA Repair | 1 | 2006 | 127 | 0.060 |
Why?
|
| Mice, SCID | 3 | 2015 | 238 | 0.060 |
Why?
|
| Prognosis | 1 | 2010 | 2093 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 61 | 0.060 |
Why?
|
| Autocrine Communication | 1 | 2004 | 37 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 191 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 597 | 0.060 |
Why?
|
| Transfection | 2 | 2016 | 782 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 196 | 0.060 |
Why?
|
| Cell Communication | 1 | 2004 | 116 | 0.060 |
Why?
|
| Insulin | 2 | 2017 | 619 | 0.060 |
Why?
|
| Biomarkers | 2 | 2021 | 1593 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 163 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2002 | 6 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2002 | 14 | 0.050 |
Why?
|
| Alkaline Phosphatase | 1 | 2022 | 71 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 87 | 0.050 |
Why?
|
| Nociception | 1 | 2022 | 5 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2022 | 69 | 0.050 |
Why?
|
| CD58 Antigens | 1 | 2022 | 4 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2016 | 631 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 201 | 0.050 |
Why?
|
| Diet, Gluten-Free | 1 | 2022 | 4 | 0.050 |
Why?
|
| Trypsin Inhibitors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 137 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 375 | 0.050 |
Why?
|
| Duodenum | 1 | 2022 | 47 | 0.050 |
Why?
|
| Protein Binding | 2 | 2003 | 1027 | 0.050 |
Why?
|
| Flavonoids | 1 | 2022 | 109 | 0.050 |
Why?
|
| Immunomodulation | 1 | 2022 | 35 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2022 | 35 | 0.050 |
Why?
|
| Symbiosis | 1 | 2022 | 19 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2022 | 24 | 0.050 |
Why?
|
| Receptor, IGF Type 2 | 1 | 2001 | 13 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2019 | 753 | 0.050 |
Why?
|
| Human Growth Hormone | 1 | 2001 | 20 | 0.050 |
Why?
|
| Immunity | 1 | 2022 | 67 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2022 | 144 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 164 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2001 | 42 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 50 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2021 | 22 | 0.050 |
Why?
|
| Toxicity Tests, Subchronic | 1 | 2021 | 3 | 0.050 |
Why?
|
| Glucuronides | 1 | 2021 | 5 | 0.050 |
Why?
|
| Leptin | 1 | 2021 | 80 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2022 | 122 | 0.050 |
Why?
|
| 3T3 Cells | 2 | 2016 | 124 | 0.050 |
Why?
|
| Spheroids, Cellular | 1 | 2021 | 45 | 0.050 |
Why?
|
| Organ Size | 1 | 2021 | 242 | 0.050 |
Why?
|
| Receptors, Bombesin | 1 | 2000 | 3 | 0.050 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 2000 | 3 | 0.050 |
Why?
|
| Hormone Antagonists | 1 | 2000 | 6 | 0.050 |
Why?
|
| Helicobacter | 1 | 2020 | 5 | 0.050 |
Why?
|
| Lactobacillus | 1 | 2020 | 6 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2021 | 222 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2000 | 71 | 0.050 |
Why?
|
| Lyme Disease | 1 | 2020 | 17 | 0.050 |
Why?
|
| Epithelium | 1 | 2000 | 172 | 0.050 |
Why?
|
| Disease Progression | 2 | 2018 | 1038 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2022 | 211 | 0.050 |
Why?
|
| Bacteria | 1 | 2022 | 193 | 0.050 |
Why?
|
| North America | 1 | 2020 | 112 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2000 | 114 | 0.040 |
Why?
|
| Spleen | 1 | 2021 | 301 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2021 | 193 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2021 | 324 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 186 | 0.040 |
Why?
|
| Intestinal Absorption | 1 | 2019 | 41 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 53 | 0.040 |
Why?
|
| Metronidazole | 1 | 2019 | 28 | 0.040 |
Why?
|
| Indoles | 1 | 2020 | 146 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 79 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2019 | 90 | 0.040 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 17 | 0.040 |
Why?
|
| Peptides | 1 | 2022 | 455 | 0.040 |
Why?
|
| Mast Cells | 1 | 2019 | 113 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2020 | 312 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2021 | 295 | 0.040 |
Why?
|
| Streptomycin | 1 | 2018 | 12 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2018 | 14 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 179 | 0.040 |
Why?
|
| Vancomycin | 1 | 2018 | 60 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 422 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1745 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 329 | 0.040 |
Why?
|
| Neomycin | 1 | 2018 | 56 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 981 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 69 | 0.040 |
Why?
|
| Lipids | 1 | 2019 | 298 | 0.040 |
Why?
|
| Liposomes | 1 | 2017 | 107 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 65 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 304 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 61 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2016 | 55 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 2016 | 88 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 207 | 0.030 |
Why?
|
| Mutation | 2 | 2016 | 1213 | 0.030 |
Why?
|
| RAW 264.7 Cells | 1 | 2016 | 42 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 80 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2016 | 25 | 0.030 |
Why?
|
| Kidney | 1 | 2021 | 945 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 850 | 0.030 |
Why?
|
| Histones | 1 | 2016 | 111 | 0.030 |
Why?
|
| Carcinogens | 1 | 2016 | 86 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 306 | 0.030 |
Why?
|
| Sucrose | 1 | 2015 | 58 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 235 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 42 | 0.030 |
Why?
|
| Cricetinae | 1 | 2015 | 262 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2021 | 824 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 786 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 260 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2015 | 152 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 499 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 901 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2015 | 7029 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2015 | 231 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 1200 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 111 | 0.030 |
Why?
|
| Granuloma, Pyogenic | 1 | 2013 | 5 | 0.030 |
Why?
|
| Adolescent | 1 | 2006 | 8912 | 0.030 |
Why?
|
| Root Canal Therapy | 1 | 2013 | 2 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 384 | 0.030 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 7 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 51 | 0.030 |
Why?
|
| Postmenopause | 1 | 2013 | 93 | 0.030 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Maxilla | 1 | 2013 | 63 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2012 | 176 | 0.030 |
Why?
|
| Radiography, Panoramic | 1 | 2011 | 8 | 0.030 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2011 | 52 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 800 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 617 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 2176 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1553 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1641 | 0.020 |
Why?
|
| Vimentin | 1 | 2008 | 47 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 700 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 62 | 0.020 |
Why?
|
| Radiculopathy | 1 | 2008 | 15 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 2334 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 434 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 53 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2006 | 134 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 76 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 682 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 282 | 0.020 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2005 | 2 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2005 | 6 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 25 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 1204 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2005 | 56 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2005 | 58 | 0.020 |
Why?
|
| Heterozygote | 1 | 2005 | 174 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2008 | 506 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 948 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 48 | 0.010 |
Why?
|
| Culture Media | 1 | 2003 | 155 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 453 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2005 | 332 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 322 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 258 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 171 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 317 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 5717 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 5300 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 2223 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2324 | 0.010 |
Why?
|